The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Inclusion Criteria:

• Histologic or cytologic confirmation of NSCLC (locally advanced or metastatic, IB-IV)
• Failure of first-line platinum-based chemotherapy

Exclusion Criteria:

• Mixed small cell or non-small-cell histology
• Bronchoalveolar carcinoma
• Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin)
• Prior treatment with docetaxel